期刊
LUNG CANCER
卷 74, 期 3, 页码 510-515出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2011.05.008
关键词
Non-small cell lung carcinoma; Time-resolved fluorescence immunoassays; Urokinase plasminogen activator receptor; uPAR; Cleaved uPAR; Prognosis
资金
- Danish Cancer Society
- Danish Research School in Molecular Cancer Research (MCRS)
Objectives: To study the prognostic impact of the different forms of the receptor for urokinase plasminogen activator (uPAR) in serum from 171 non-small cell lung cancer (NSCLC) patients. Materials and methods: Serum sampled preoperatively was available from 171 patients radically resected for NSCLC. Intact uPAR, uPAR(I-III), intact and cleaved uPAR, uPAR(I-III)+uPAR(II-III) and the liberated uPAR(I) were measured by time-resolved fluorescence immunoassays (TR-FlAs 1-3). Results: High serum levels of each of the three uPAR forms were associated with short overall survival (OS). In a multivariate survival analysis uPAR(I-III) (hazard ratio (HR) = 2.3.95% confidence interval (CI): 1.2-4.5, p=0.015) and uPAR(I) (hazard ratio (HR) = 1.5, 95% CI: 1.0-2.2, p=0.0497) remained significant prognostic parameters independent of stage, histology, age, performance status and therapy. Conclusions: This retrospective study shows that uPAR(I-III) and uPAR(I) in serum are independent prognostic factors in patients radically operated for NSCLC. Further prospective studies are needed to validate these markers for clinical use. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据